Avatrombopag Maleate

马来酸阿伐曲泊帕

Report date: 2026/03/06 20:02:51
NME

Base Information

Drug NameAvatrombopag Maleate
Drug Alias Name马来酸阿伐琼珀Avatrombopagumavatrombopag阿伐曲泊帕Doptelet +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionThrombopoietin receptor agonists
TargetsThrombopoietin receptor
Therapy Area/IndicationsDrug-Related Side Effects and Adverse ReactionsThrombocytopeniaPurpura, Thrombocytopenic, Idiopathic +[7] 
Global Approved IndicationsThrombocytopeniaLiver Diseases
Approved Indications in ChinaThrombocytopeniaLiver Diseases
Original Approved Country/TerritoryUnited States
Original Approved Date2018/05/21
Country/TerritoryCzechiaBelgiumBulgaria +[35] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstellas Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesSwedish Orphan Biovitrum AgSobiGyre Pharmaceuticals Ltd +[8] 
Inactive CompaniesUniversity Of RochesterDova Pharmaceuticals IncPharma Packaging Solutions +[10] 
Active IndicationsThrombocytopeniaPurpura, Thrombocytopenic, IdiopathicAnemia, Aplastic +[4] 
Inactive IndicationsDrug-Related Side Effects and Adverse ReactionsCardiovascular DiseasesLymphoma

Other Information

ATC CodeB02BX
Related LinksWikipediaDrugBankKEGG